{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:06:40Z","timestamp":1793869600932,"version":"4.6.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["25 4339 Pj"],"award-info":[{"award-number":["25 4339 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2025\\u201303049"],"award-info":[{"award-number":["2025\\u201303049"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010223","name":"Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007230","name":"Foundation King Gustaf V Jubilee Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"publisher","award":["SSMF CG-23\\u20130056-B"],"award-info":[{"award-number":["SSMF CG-23\\u20130056-B"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116833","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:39:21Z","timestamp":1779583161000},"page":"116833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III\u2013IV melanoma: A retrospective cohort study"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8898-8301","authenticated-orcid":false,"given":"Axel","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Alghaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-8870","authenticated-orcid":false,"given":"Karl","family":"Bj\u00f6rkstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0017-7377","authenticated-orcid":false,"given":"Ellen","family":"Krabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2389-9034","authenticated-orcid":false,"given":"Sophie","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-1485","authenticated-orcid":false,"given":"M\u00e5ns","family":"Kadefors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Wallander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-0188","authenticated-orcid":false,"given":"Sara","family":"Bjursten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav J.","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1818-7008","authenticated-orcid":false,"given":"Ana","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-4771","authenticated-orcid":false,"given":"Hildur","family":"Helgadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0355","authenticated-orcid":false,"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116833_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41577-018-0008-4","article-title":"Clocking in to immunity","volume":"18","author":"Scheiermann","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2026.116833_bib2","article-title":"Timing of immune checkpoint blockade shapes anti-tumor immunity via a clock-dependent chemokine axis","author":"Lichterman","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejca.2026.116833_bib3","article-title":"Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial","author":"Huang","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116833_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116833_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116833_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116833_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115485","article-title":"Neoadjuvant immunotherapy for patients with resectable stage III\/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL)","volume":"224","author":"Nelson","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116833_bib8","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116833_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2025.103371","article-title":"The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: a retrospective observational study","volume":"152","author":"Amici","year":"2025","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ejca.2026.116833_bib10","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the american joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.116833_bib11","doi-asserted-by":"crossref","unstructured":"Peters, S.D., U.; Ballinger, M.; Christopeit, M.; Dimopoulou, G.; Perol, M.; Provencio Pulla, M.; Reck, M.; Smit, E.F.; Tsourti, Z.; Morris, S.; Stahel, R.A. ETOP-Roche i-TIMES: Immunotherapy timing investigation on lung cancer survival. in European Lung Cancer Congress (ELCC) (Paris, France., 2026).","DOI":"10.1016\/j.esmoop.2026.106958"},{"key":"10.1016\/j.ejca.2026.116833_bib12","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116833_bib13","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:48:34Z","timestamp":1783486114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":13,"alternative-id":["S0959804926006143"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116833","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III\u2013IV melanoma: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116833"}}